Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Fluids and Barriers of the CNS
Published in: Fluids and Barriers of the CNS 1/2021

Open Access 01-12-2021 | Obesity | Review

SARS-CoV-2: is there neuroinvasion?

Authors: Conor McQuaid, Molly Brady, Rashid Deane

Published in: Fluids and Barriers of the CNS | Issue 1/2021

Login to get access

Abstract

Background

SARS-CoV-2, a coronavirus (CoV), is known to cause acute respiratory distress syndrome, and a number of non-respiratory complications, particularly in older male patients with prior health conditions, such as obesity, diabetes and hypertension. These prior health conditions are associated with vascular dysfunction, and the CoV disease 2019 (COVID-19) complications include multiorgan failure and neurological problems. While the main route of entry into the body is inhalation, this virus has been found in many tissues, including the choroid plexus and meningeal vessels, and in neurons and CSF.

Main body

We reviewed SARS-CoV-2/COVID-19, ACE2 distribution and beneficial effects, the CNS vascular barriers, possible mechanisms by which the virus enters the brain, outlined prior health conditions (obesity, hypertension and diabetes), neurological COVID-19 manifestation and the aging cerebrovascualture. The overall aim is to provide the general reader with a breadth of information on this type of virus and the wide distribution of its main receptor so as to better understand the significance of neurological complications, uniqueness of the brain, and the pre-existing medical conditions that affect brain. The main issue is that there is no sound evidence for large flux of SARS-CoV-2 into brain, at present, compared to its invasion of the inhalation pathways.

Conclusions

While SARS-CoV-2 is detected in brains from severely infected patients, it is unclear on how it gets there. There is no sound evidence of SARS-CoV-2 flux into brain to significantly contribute to the overall outcomes once the respiratory system is invaded by the virus. The consensus, based on the normal route of infection and presence of SARS-CoV-2 in severely infected patients, is that the olfactory mucosa is a possible route into brain. Studies are needed to demonstrate flux of SARS-CoV-2 into brain, and its replication in the parenchyma to demonstrate neuroinvasion. It is possible that the neurological manifestations of COVID-19 are a consequence of mainly cardio-respiratory distress and multiorgan failure. Understanding potential SARS-CoV-2 neuroinvasion pathways could help to better define the non-respiratory neurological manifestation of COVID-19.
Literature
1.
2.
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288:192–206.PubMedCrossRef
3.
Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–8.PubMedPubMedCentralCrossRef
4.
5.
6.
Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7(11):ofaa507.PubMedPubMedCentralCrossRef
7.
8.
9.
Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020;52(05):257–63.PubMedPubMedCentralCrossRef
10.
11.
Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–60.PubMedPubMedCentralCrossRef
12.
Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci NLM (Medline). 2020;16:1753–66.CrossRef
13.
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–68.PubMedPubMedCentralCrossRef
14.
‘Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020;157(January):19–20.
15.
16.
17.
Ramphul K, Mejias SG. Kawasaki disease: a comprehensive review. Arch Med Sci Atheroscler Dis. 2018;3(1):41–5.CrossRef
18.
19.
Ya M. Properties of coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3–11.
20.
Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou J-J, et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 2020;583:286–9.PubMedCrossRef
21.
Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci. 2020;11(9):1206–9.PubMedCrossRef
22.
Ortega JT, Serrano ML, Pujol FH, Rangel HR. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: an in silico analysis. EXCLI J. 2020;19:410–7.PubMedPubMedCentral
23.
24.
Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020 Mar 14;2020.03.14.988345.
25.
Avolio E, Gamez M, Kapil Gupta ;, Foster R, Berger I, Caputo M, et al. The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes—endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. https://​doi.​org/​10.​1101/​2020.​12.​21.​423721
26.
Alejandra Tortorici M, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26(6):481–9.PubMedPubMedCentralCrossRef
27.
28.
Rathnasinghe R, Jangra S, Cupic A, Martínez-Romero C, Mulder LCF, Kehrer T, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera Contributed equally. medRxiv. 2021;2021.01.19.21249592.
29.
Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64-75.e11.PubMedPubMedCentralCrossRef
30.
Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-827.e19.PubMedPubMedCentralCrossRef
31.
Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y, et al. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol. 2014;95(PART3):614–26.PubMedCrossRef
32.
33.
Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2021;370(6523):1464–8.CrossRef
34.
35.
36.
Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bioRxiv. 2021 Jan 4;2020.12.31.425021.
37.
Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020;183(7):1901-1912.e9.PubMedPubMedCentralCrossRef
38.
Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2—what do they mean? JAMA. 2021;325:529–31.PubMedCrossRef
39.
WHO | SARS-CoV-2 mink-associated variant strain—Denmark. WHO. 2020.
40.
Maison DP, Ching LL, Shikuma CM, Nerurkar VR. Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawaii Reveals the Worldwide Emerging P681H Mutation. bioRxiv. 2021 Jan 7;2021.01.06.425497.
41.
Wang R, Chen J, Gao K, Hozumi Y, Yin C, Wei G-W. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants. Commun Biol. 2021;4(1):228.PubMedPubMedCentralCrossRef
42.
Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011;3(84):84ra44–84ra44.
43.
Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020;323:2089–90.PubMedPubMedCentralCrossRef
44.
45.
Mallard C. Innate immune regulation by toll-like receptors in the brain. International Scholarly Research Network ISRN Neurology. 2012.
46.
47.
48.
See H, Wark P. Innate immune response to viral infection of the lungs. Paediatr Respir Rev. 2008;8:243–50.CrossRef
49.
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.PubMedPubMedCentralCrossRef
50.
51.
52.
Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Investig. 2019;129(9):3625–39.PubMedPubMedCentralCrossRef
53.
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.PubMedCrossRef
54.
Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26:485–95.PubMedCrossRef
55.
56.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5).
57.
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemostasis 2020.
58.
Rodríguez A, Tjärnlund A, Ivanji J, Singh M, García I, Williams A, et al. Role of IgA in the defense against respiratory infections: IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine. 2005;23(20):2565–72.PubMedCrossRef
59.
60.
61.
62.
Chen HD, Fraire AE, Joris I, Welsh RM, Selin LK. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. American Journal of Pathology [Internet]. 2003 Oct 1. 163(4):1341–55. https://​pubmed.​ncbi.​nlm.​nih.​gov/​14507643/​. Accessed 6 June 2021.
63.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;28:1–12.
64.
Yilla M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS, et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res. 2005;107(1):93–101.PubMedCrossRef
65.
Campillo-Navarro M, Chávez-Blanco AD, Wong-Baeza I, Serafín-López J, Flores-Mejía R, Estrada-Parra S, et al. Mast cells in lung homeostasis: Beyond type i hypersensitivity. Corp Commun. 2005;10(2):115–23.
66.
Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The role of apelin in cardiovascular diseases, obesity and cancer. Vol. 9, Frontiers in Physiology. Frontiers Media S.A.; 2018.
67.
68.
Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77:301–8.PubMedCrossRef
69.
Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry. Proc Natl Acad Sci USA. 2008;105(22):7809–14.PubMedPubMedCentralCrossRef
70.
Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care. 2020;24:221.PubMedPubMedCentralCrossRef
71.
Beneteau-Burnat B, Baudin B, Morgant G, Baumann FC, Giboudeau J. Serum angiotensin-converting enzyme in healthy and sarcoidotic children: Comparison with the reference interval for adults. Clin Chem. 1990;36(2):344–6.PubMedCrossRef
72.
Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.PubMedPubMedCentralCrossRef
73.
Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280(34):30113–9.PubMedCrossRef
74.
Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;1(66):167–76.CrossRef
75.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20.PubMedCrossRef
76.
Sun P, Lu X, Xu C, Wang Y, Sun W, Xi J. CD-sACE2 inclusion compounds: an effective treatment for coronavirus disease 2019 (COVID-19). J Med Virol. 2020;92:1721–3.PubMedCrossRef
77.
Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care. 2020;24:1–3.CrossRef
78.
Hoffmann M, Kleine-Weber H, Schroeder S, Mü MA, Drosten C, Pö S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.PubMedPubMedCentralCrossRef
79.
McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al. The brain renin-angiotensin system: Location and physiological roles. Int J Biochem Cell Biol. 2003;35:901–18.PubMedCrossRef
80.
Carey RM. The intrarenal renin-angiotensin system in hypertension. Adv Chronic Kidney Dis. 2015;22:204–10.PubMedCrossRef
81.
Alenina N, Bader M. ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models. Neurochem Res. 2019;44(6):1323–9.PubMedCrossRef
82.
Zhang Q, Cong M, Wang N, Li X, Zhang H, Zhang K, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender a case–control study. Medicine. 2018;97(42):e12917.PubMedPubMedCentralCrossRef
83.
Evans CE, Miners JS, Piva G, Willis CL, Heard DM, Kidd EJ, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease. Acta Neuropathol. 2020;139(3):485–502.PubMedPubMedCentralCrossRef
84.
Li L-J, Zhang F-B, Liu S-Y, Tian Y-H, Le F, Wang L-Y, et al. Human sperm devoid of germinal angiotensin-converting enzyme is responsible for total fertilization failure and lower fertilization rates by conventional in vitro fertilization. Biol Reprod. 2014;90(6):125.PubMedCrossRef
85.
Hemnes AR, Rathinasabapathy A, Austin EA, Brittain EL, Carrier EJ, Chen X, et al. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51(6):1702638.PubMedPubMedCentralCrossRef
86.
87.
88.
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6.PubMedPubMedCentralCrossRef
89.
Da Silva JS, Gabriel-Costa D, Wang H, Ahmad S, Sun X, Varagic J, et al. Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. J Renin-Angiotensin-Aldosterone Syst 2017. Doi: https://​doi.​org/​10.​1177/​1470320317722270​
90.
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.PubMedPubMedCentralCrossRef
91.
Xu D, Ma M, Xu Y, Su Y, Ong S-B, Hu X, et al. Single-cell transcriptome analysis indicates new potential regulation mechanism of ACE2 and NPs signaling among heart failure patients infected with SARS-CoV-2 2 3.
92.
Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1–5.CrossRef
93.
Sakima A, Averill DB, Gallagher PE, Kasper SO, Tommasi EN, Ferrario CM, et al. Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1–7) at the nucleus tractus solitarii. Hypertension. 2005;46(2):333–40.PubMedCrossRef
94.
Elased KM, Cunha TS, Gurley SB, Coffman TM, Morris M. New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension. 2006;47(5):1010–7.PubMedCrossRef
95.
96.
97.
Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007;292(1):R373–81.PubMedCrossRef
98.
Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, Bullock TA, McGary HM, Khan JA, et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier. Neurobiol Dis. 2020;146:105131.PubMedPubMedCentralCrossRef
99.
Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020 Jun 22;2020.06.22.20137273.
100.
Ghobrial M, Charish J, Takada S, Valiante T, Monnier PP, Radovanovic I, et al. The human brain vasculature shows a distinct expression pattern of SARS-CoV-2 entry factors. bioRxiv. 2020.
101.
He L, Mäe MA, Sun Y, Muhl L, Nahar K, Liébanas EV, et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2—implications for microvascular inflammation and hypercoagulopathy in COVID-19 patients. bioRxiv. 2020 May 12;2020.05.11.088500.
102.
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.PubMedPubMedCentralCrossRef
103.
Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552–5.PubMedCrossRef
104.
Li Y, Zhang Z, Yang L, Xin S, Cao P, Lu J. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. 2020;
105.
Zlokovic BV. The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron. 2008;57:178–201.PubMedCrossRef
106.
Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC. The blood-brain barrier: an engineering perspective. Front Neuroeng. 2013;6(JUL):1–22.
107.
Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28(4):202–8.PubMedCrossRef
108.
Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc Res. 1999;58(3):312–28.PubMedCrossRef
109.
Rhea EM, Salameh TS, Logsdon AF, Hanson AJ, Erickson MA, Banks WA. Blood-Brain Barriers in Obesity. AAPS Journal. 2017;19(4):921–30.CrossRef
110.
111.
Deane R, Zheng W, Zlokovic BV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem. 2004;88(4):813–20.PubMedPubMedCentralCrossRef
112.
Mw B. The structure and function of the blood-brain barrier. Fed Proc. 1984;43(2):186–90.
113.
Zheng W, Deane R, Redzic Z, Preston JE, Segal MB. Transport of L-[125I]thyroxine by in situ perfused ovine choroid plexus: inhibition by lead exposure. J Toxicol Environ Health Part A. 2003;66(5):435–51.CrossRef
114.
Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cerebral Blood Flow Metabol. 2009;29(1):25–33.CrossRef
115.
116.
117.
Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.PubMedCrossRef
118.
Jiménez AJ, Domínguez-Pinos MD, Guerra MM, Fernández-Llebrez P, Pérez-Fígares JM. Structure and function of the ependymal barrier and diseases associated with ependyma disruption. Tissue Barriers. 2014;2:1–14.CrossRef
119.
120.
Bouillé C, Mesnil M, Barriere H, Gabrion J. Gap junctional intercellular communication between cultured ependymal cells, revealed by lucifer yellow CH transfer and freeze-fracture. Glia. 1991;4(1):25–36.PubMedCrossRef
121.
122.
Söhl G, Odermatt B, Maxeiner S, Degen J, Willecke K. New insights into the expression and function of neural connexins with transgenic mouse mutants. In: Brain Research Reviews. Brain Res Brain Res Rev; 2004. p. 245–59.
123.
Yamamoto T, Kardami E, Nagy JI. Basic fibroblast growth factor in rat brain: localization to glial gap junctions correlates with connexin43 distribution. Brain Res. 1991;554(1–2):336–43.PubMedCrossRef
124.
Banizs B, Pike MM, Millican CL, Ferguson WB, Komlosi P, Sheetz J, et al. Dysfunctional cilia lead to altered ependyma and choroid plexus function, and result in the formation of hydrocephalus. Development. 2005;132(23):5329–39.PubMedCrossRef
125.
126.
Liddelow SA. Development of the choroid plexus and blood-CSF barrier. Vol. 9, Frontiers in Neuroscience. Frontiers Media S.A.; 2015.
127.
Davson H, Segal MB. Effect of cerebrospinal fluid on volume of distribution of extracellular markers. Vol. 92, Brain. 1969.
128.
Davson H, Segal MB. The effects of some inhibitors and accelerators of sodium transport on the turnover of 22Na in the cerebrospinal fluid and the brain. J Physiol. 1970;209(1):131–53.PubMedPubMedCentralCrossRef
129.
Davson H, Hollingsworth G, Segal MB. The mechanism of drainage of the cerebrospinal fluid. Vol. 93, Brain. 1970.
130.
Davson H, Segal MB, Malcolm B. Physiology of the CSF and blood-brain barriers. CRC Press; 1996, p. 822.
131.
Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008;5:32.CrossRef
132.
Pollay M. The function and structure of the cerebrospinal fluid outflow system. Cerebrospinal Fluid Res. 2010;7:20.CrossRef
133.
134.
Fame RM, Lehtinen MK. Emergence and developmental roles of the cerebrospinal fluid system. Developmental Cell. Cell Press; 2020. p. 261–75.
135.
Bradbury MW, Westrop RJ. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol. 1983;339(1):519–34.PubMedPubMedCentralCrossRef
136.
Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res. 2004;1(1):1–3.CrossRef
137.
Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol. 1993;19(6):480–8.PubMedCrossRef
138.
Brady M, Rahman A, Combs A, Venkatraman C, Kasper RT, McQuaid C, et al. Cerebrospinal fluid drainage kinetics across the cribriform plate are reduced with aging. Fluids Barriers CNS. 2020;17(1):71.PubMedPubMedCentralCrossRef
139.
Davson H, Welch K, Segal MB. The physiology and pathophysiology of the cerebrospinal fluid. Ann Neurol. 1987;24(1):106–106.
140.
141.
142.
Falangola MF, Hanly A, Galvao-Castro B, Petito CK. HIV infection of human choroid plexus: a possible mechanism of viral entry into the CNS. J Neuropathol Exp Neurol. 1995;54(4):497–503.PubMedCrossRef
143.
Bragg DC, Childers TA, Tompkins MB, Tompkins WA, Meeker RB. Infection of the choroid plexus by feline immunodeeciency virus. J Neurovirol. 2002;8:211–24.PubMedCrossRef
144.
145.
Finsterer, Josef Stollberger C. Update on the neurology of COVID-19. 2020;0–3.
146.
Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;1(94):55–8.CrossRef
147.
Huang YH, Jiang D, Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immunity. 2020;87:149.CrossRef
148.
Garg R. Spectrum of neurological manifestations in covid-19: a review. Neurol India. 2020;68(3):560.PubMedCrossRef
149.
Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Berlin: Nature Publishing Group; 2017.CrossRef
150.
Bajénoff M, Germain RN. Seeing is believing: a focus on the contribution of microscopic imaging to our understanding of immune system function. Eur J Immunol. 2007;37(SUPPL. 1):S18-33.PubMedCrossRef
151.
Bousso P, Bhakta NR, Lewis RS, Robey E. Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy. Science. 2002;296(5574):1876–80.PubMedCrossRef
152.
153.
Hoeve MA, Nash AA, Jackson D, Randall RE, Dransfield I. Influenza virus A infection of human monocyte and macrophage subpopulations reveals increased susceptibility associated with cell differentiation. PLoS ONE. 2012;7(1):29443.CrossRef
154.
155.
156.
157.
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020;
158.
Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279–84.PubMedPubMedCentralCrossRef
159.
Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson’s resting tremor. CNS Neurosci Ther. 2017;23(3):209–15.PubMedPubMedCentralCrossRef
160.
Ehgoetz Martens KA, Hall JM, Georgiades MJ, Gilat M, Walton CC, Matar E, et al. The functional network signature of heterogeneity in freezing of gait. Brain. 2018;141(4):1145–60.PubMedCrossRef
161.
Macht M, Kaussner Y, Möller JC, Stiasny-Kolster K, Eggert KM, Krüger HP, et al. Predictors of freezing in Parkinson’s disease: a survey of 6,620 patients. Mov Disord. 2007;22(7):953–6.PubMedCrossRef
162.
Zach H, Dirkx M, Pasman JW, Bloem BR, Helmich RC. The patient’s perspective: the effect of levodopa on Parkinson symptoms. Parkinsonism Relat Disord. 2017;1(35):48–54.CrossRef
163.
Castelnuovo G, Zhu X, Francisco R, Pedro M, Delvecchio E, Pedro Espada J, et al. Psychological symptoms and behavioral changes in children and adolescents during the early phase of COVID-19 quarantine in three European Countries. Frontiers in Psychiatry | www.​frontiersin.​org [Internet]. 2020;11:570164. www.​frontiersin.​org
164.
Knell G, Robertson MC, Dooley EE, Burford K, Mendez KS. Health behavior changes during covid-19 pandemic and subsequent “stay-at-home” orders. Int J Environ Res Public Health. 2020;17(17):1–16.CrossRef
165.
166.
Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, et al. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med. 2016;375(5):497–8.PubMedCrossRef
167.
Yeh EA, Collins A, Cohen ME, Duffner PK, Faden H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics. 2004;113(1 Pt 1):e73–6.PubMed
168.
Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. 2020;77(11):1366–72.CrossRef
169.
170.
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of covid-19 in the young. N Engl J Med. 2020;382(20):e60.PubMedCrossRef
171.
Belani P, Schefflein J, Kihira S, Rigney B, Delman BN, Mahmoudi K, et al. COVID-19 Is an independent risk factor for acute ischemic stroke. Am J Neuroradiol. 2020;41(8):1361–4.PubMedCrossRefPubMedCentral
172.
Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J NeuroIntervent Surg. 2020;12(7):648–53.CrossRef
173.
Majidi S, Fifi JT, Ladner TR, Lara-Reyna J, Yaeger KA, Yim B, et al. Emergent large vessel occlusion stroke during New York City’s COVID-19 outbreak: clinical characteristics and paraclinical findings. Stroke. 2020;51(9):2656–63.PubMedPubMedCentralCrossRef
174.
Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–11.PubMedCrossRef
175.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395(10234):1417–8.CrossRef
176.
Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine. 2020;24:100434.PubMedPubMedCentralCrossRef
177.
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–82.PubMedPubMedCentralCrossRef
178.
179.
Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089–96.PubMedCrossRef
180.
Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol. 2017;13(3):227–33.PubMedPubMedCentralCrossRef
181.
McCray PB, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–21.PubMedCrossRef
182.
St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol. 2004;78(16):8824–34.PubMedPubMedCentralCrossRef
183.
Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75.PubMedPubMedCentralCrossRef
184.
Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2015;212(11):712–22.
185.
Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12:24.CrossRef
186.
Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, et al. SARS-CoV-2 infects brain choroid plexus and disrupts the blood-CSF-barrier. bioRxiv. 2020 Aug 21;2020.08.20.259937.
187.
Giri R, Shen Y, Stins M, Du YS, Schmidt AM, Stern D, et al. β-Amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 2000;279(6):48–56.CrossRef
188.
Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD. Exploring Braak’s hypothesis of parkinson’s disease. Front Neurol. 2017;8(FEB):1.
189.
Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11:1200–3.PubMedCrossRef
190.
Audrit KJ, Delventhal L, Aydin Ö, Nassenstein C. The nervous system of airways and its remodeling in inflammatory lung diseases. Cell Tissue Res. 2017;367:571–90.PubMedCrossRef
191.
Driessen AK, Farrell MJ, Mazzone SB, McGovern AE. Multiple neural circuits mediating airway sensations: recent advances in the neurobiology of the urge-to-cough. Respir Physiol Neurobiol. 2016;1(226):115–20.CrossRef
192.
Sorby-Adams AJ, Marcoionni AM, Dempsey ER, Woenig JA, Turner RJ. The role of neurogenic inflammation in blood-brain barrier disruption and development of cerebral oedema following acute central nervous system (CNS) injury. Int J Mol Sci. 2017;18:1788.PubMedCentralCrossRef
193.
von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. 2020;395:e109.CrossRef
194.
Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol. 2020;77:1028–9.PubMedCrossRef
195.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11:995.PubMedCrossRef
196.
197.
198.
Ramani A, Müller L, Ostermann PN, Gabriel E, Abida-Islam P, Müller-Schiffmann A, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230.PubMedPubMedCentralCrossRef
199.
Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. 2021;218(3):e20202135.PubMedPubMedCentralCrossRef
200.
Murray RS, Cai GY, Hoel K, Zhang JY, Soike KF, Cabirac GF. Coronavirus infects and causes demyelination in primate central nervous system. Virology. 1992;188(1):274–84.PubMedCrossRef
201.
De Santis G. SARS-CoV-2: a new virus but a familiar inflammation brain pattern. Brain Behav Immunity. 2020;347(xxxx):1–2.
202.
Butler N, Pewe L, Trandem K, Perlman S. Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated. Virology. 2006;347(2):410–21.PubMedCrossRef
203.
Hachem M. SARS-CoV-2 journey to the brain with a focus on potential role of docosahexaenoic acid bioactive lipid mediators. Biochimie. 2021;184:95–103.PubMedPubMedCentralCrossRef
204.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.PubMedPubMedCentralCrossRef
205.
L C, HG L, W L, J L, K L, J S, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2020;43(0).
206.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan. China Clin Infect Dis. 2020;71(15):762–8.PubMedCrossRef
207.
Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou. China Immunol. 2020;160(3):261–8.CrossRef
208.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497–506.PubMedPubMedCentralCrossRef
209.
Liu F, Li L, Da XuM, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.PubMedPubMedCentralCrossRef
210.
211.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.PubMedPubMedCentralCrossRef
212.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.CrossRefPubMed
213.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars Immunopathol. 2017;39:529–39.CrossRef
214.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.PubMedPubMedCentralCrossRef
215.
Chen J, Subbarao K. The immunobiology of SARS. Annu Rev Immunol. 2007;45:443–72.CrossRef
216.
Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81(16):8692–706.PubMedPubMedCentralCrossRef
217.
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon-γ-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185–94.PubMedCrossRef
218.
219.
Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis. 2004;189(4):648–51.PubMedCrossRef
220.
Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, et al. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. MBio. 2014;5(3):e01174-e1214.PubMedPubMedCentralCrossRef
221.
Lau SKP, Lau CCY, Chan KH, Li CPY, Chen H, Jin DY, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013;94(PART 12):2679–90.
222.
Yen Y-T, Liao F, Hsiao C-H, Kao C-L, Chen Y-C, Wu-Hsieh BA. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006;80(6):2684–93.PubMedPubMedCentralCrossRef
223.
Tynell J, Westenius V, Rönkkö E, Munster VJ, Melén K, Österlund P, et al. Middle east respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol. 2016;97(2):344–55.PubMedPubMedCentralCrossRef
224.
Zhou J, Chu H, Li C, Wong BHY, Cheng ZS, Poon VKM, et al. Active replication of middle east respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis. J Infect Dis. 2014;209(9):1331–42.PubMedCrossRef
225.
Law HKW, Chung YC, Hoi YN, Sin FS, Yuk OC, Luk W, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–74.PubMedCrossRef
226.
Cheung CY, Poon LLM, Ng IHY, Luk W, Sia S-F, Wu MHS, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819–26.PubMedPubMedCentralCrossRef
227.
228.
de Vries HE, Blom-Roosemalen MCM, van Oosten M, de Boer AG, van Berkel TJC, Breimer DD, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37–43.PubMedCrossRef
229.
Banks WA. The blood-brain barrier in neuroimmunology: Tales of separation and assimilation. Brain Behav Immunity. 2015;44:1–8.CrossRef
230.
Banks W. Blood-Brain Barrier transport of cytokines: a mechanism for neuropathology. Curr Pharma Design. 2005;11(8):973–84.CrossRef
231.
232.
Buttler L, Jordão MT, Fragas MG, Ruggeri A, Ceroni A, Michelini LC. Maintenance of blood-brain barrier integrity in hypertension: a novel benefit of exercise training for autonomic control. Front Physiol. 2017;8(DEC):1–14.
233.
234.
Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68(3):409–27.PubMedPubMedCentralCrossRef
235.
Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 2001;893(1–2):104–12.PubMedCrossRef
236.
Wei M, Li H, Shang Y, Zhou Z, Zhang J. Increased CD147 (EMMPRIN) expression in the rat brain following traumatic brain injury. Brain Res. 2014;17(1585):150–8.CrossRef
237.
Pan P, Zhao H, Zhang X, Li Q, Qu J, Zuo S, et al. Cyclophilin a signaling induces pericyte-associated blood-brain barrier disruption after subarachnoid hemorrhage. J Neuroinflammation. 2020;17(1):16.PubMedPubMedCentralCrossRef
238.
Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50(1):202–11.PubMedCrossRef
239.
Kress BT, Iliff JJ, Xia M, Wang M, Wei Bs HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76(6):845–61.PubMedPubMedCentralCrossRef
240.
Erickson MA, Banks WA. Age-associated changes in the immune system and blood–brain barrier functions. Int J Mol Sci. 2019;20(7):1632.PubMedCentralCrossRef
241.
Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, et al. Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance. Proc Natl Acad Sci USA. 2013;110(36):14771–6.PubMedPubMedCentralCrossRef
242.
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model. J Clin Investig. 2005;115(11):3285–90.PubMedPubMedCentralCrossRef
243.
Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of alzheimer’s disease. Int J Mol Sci. 2017;18(9):1965.PubMedCentralCrossRef
244.
Beck J, Horikawa I, Harris C. Cellular senescence: mechanisms, morphology, and mouse models. Vet Pathol. 2020;57:747–57.PubMedCrossRef
245.
246.
247.
Montagne A, Zhao Z, Zlokovic B V. Alzheimer’s disease: a matter of blood–brain barrier dysfunction? J Exp Med 2017;jem.20171406.
248.
Patching SG. Glucose Transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol. 2017;54(2):1046–77.PubMedCrossRef
249.
Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud P-O, Keller JN, et al. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. Neuropharmacology. 2014;79:668–78.PubMedPubMedCentralCrossRef
250.
Deane R, Sagare A, Zlokovic B. The role of the cell surface LRP and soluble LRP in blood-brain barrier Aβ clearance in Alzheimer’s Disease. Curr Pharm Des. 2008;14(16):1601.PubMedPubMedCentralCrossRef
251.
252.
McLean FH, Campbell FM, Langston RF, Sergi D, Resch C, Grant C, et al. A high-fat diet induces rapid changes in the mouse hypothalamic proteome. Nutr Metab. 2019;16(1):26.CrossRef
253.
Baufeld C, Osterloh A, Prokop S, Miller KR, Heppner FL. High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia. Acta Neuropathol. 2016;132(3):361–75.PubMedPubMedCentralCrossRef
254.
Kanoski SE, Zhang Y, Zheng W, Davidson TL. The effects of a high-energy diet on hippocampal function and blood-brain barrier integrity in the rat. J Alzheimer’s Dis. 2010;21(1):207–19.CrossRef
255.
Thaler JP, Guyenet SJ, Dorfman MD, Wisse BE, Schwartz MW. Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes. 2013;62:2629–34.PubMedPubMedCentralCrossRef
256.
257.
Bogush M, Heldt NA, Persidsky Y. Blood brain barrier injury in diabetes : unrecognized effects on brain and cognition. J Neuroimmune Pharmacol. 2017;12:593–601.PubMedPubMedCentralCrossRef
258.
Gray SM, Barrett EJ. The blood-brain barrier in Diabetes Mellitus. Type 2 Diabetes and Dementia. Elsevier Inc.; 2018, p. 211–29.
259.
Hadi HA, Al-Suwaidi J. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manage. 2007;3(6):853.
260.
Setiadi A, Korim WS, Elsaafien K, Yao ST. The role of the blood–brain barrier in hypertension. Exp Physiol. 2018;103(3):337–42.PubMedCrossRef
261.
Dinner S, Borkowski J, Stump-Guthier C, Ishikawa H, Tenenbaum T, Schroten H, et al. A choroid plexus epithelial cell-based model of the human blood-cerebrospinal fluid barrier to study bacterial infection from the basolateral side. J Vis Exp. 2016;2016(111):54061.
262.
263.
264.
265.
266.
267.
Health England P. Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01. 2021.
268.
269.
Emary KRW, Golubchik T, Aley PK, Ariani C v., Angus BJ, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN Electronic Journal [Internet]. 2021. https://​www.​ssrn.​com/​abstract=​3779160. Accessed 7 Feb 2021.
270.
271.
Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv: the preprint server for biology [Internet]. 2021 Jan 25;2021.01.25.427948. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​33501442. Accessed 7 Feb 2021.
272.
Metadata
Title
SARS-CoV-2: is there neuroinvasion?
Authors
Conor McQuaid
Molly Brady
Rashid Deane
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Fluids and Barriers of the CNS / Issue 1/2021
Electronic ISSN: 2045-8118
DOI
https://doi.org/10.1186/s12987-021-00267-y

Other articles of this Issue 1/2021

Fluids and Barriers of the CNS 1/2021 Go to the issue

Research

Capsule-dependent impact of MAPK signalling on host cell invasion and immune response during infection of the choroid plexus epithelium by Neisseria meningitidis

Short paper

Brain endothelial LRP1 maintains blood–brain barrier integrity

Research

Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

Research

Disparate volumetric fluid shifts across cerebral tissue compartments with two different anesthetics

Research

Upright versus supine MRI: effects of body position on craniocervical CSF flow

Research

Direction and magnitude of cerebrospinal fluid flow vary substantially across central nervous system diseases